Fig. 5

CRT + CTX/L-NIL enhances the lymphoid tumor microenvironment. Established mEER tumors treated with CRT and/or CTX/L-NIL and were harvested similar to Fig. 1e, and tumor lymphocyte infiltrate was assessed using flow cytometry (a-e; see Additional file 1: Figure S6 for lymphocyte flow cytometry gating strategy). a Lymphoid-focused tSNE (among TCRβ⁺ cells) from flow cytometry data for each group of treatment (left) and corresponding color-map (right) with colored lymphocyte subsets listed below (N = 1 representative of 5; n = 8–9/group). b Percentage of lymphoid sub-types among total tumor infiltrating T cells (TCRβ⁺ cells), including CD8⁺ T cells (top right), CD4⁺ T cells (bottom left) and regulatory T cells (bottom right) (N = 3–4; n = 23–36/group; Tukey’s multiple comparison test for CD8⁺ T cells and Dunn’s multiple comparison test for CD4⁺ and regulatory T cells). c Ratio of CD8⁺ T cells/ regulatory T cells percentages (N = 3; n = 23–24/group; Dunn’s multiple comparison test). d Percentage of E7-Tetramer⁺ among CD8⁺ T cells (N = 5; n = 33–37/group; Dunn’s multiple comparison test). e Representative flow cytometry histograms showing KLRG-1 expression among CD8⁺ T cells expressed as the % of the maximum count (left) and cumulative median fluorescence intensity (MFI) for each treatment group (right). FMO (Fluorescence minus one) is a mixture of all antibodies permitting CD8⁺ T cell identification without the phenotypical marker of interest (N = 2, n = 12; Tukey’s multiple comparison test). All bar graphs show mean +/− SD and each dot represents an individual mouse. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001